Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The LATENT Trial: Avelumab With Valproic Acid for Virus-associated Cancer
NCT03357757Phase 2Completed
- Sponsor
- American Health Staffing Group
- Start
- Feb 2018
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, valproic acid in cancer, sponsored by American Health Staffing Group. Started Feb 2018; status: completed.
02
Drugs
avelumabvalproic acid
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03357757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357757.